|
|
|
|
|
|
|
|
If
you dont have an Acrobat Reader installed on your computer, you
may download it for free from the link below:
|
|
|
|
|
Pharmacotherapeutic Options for the
Treatment of Depression in Patients
With Chronic Kidney Disease
(Vol
35/No. 3. On-line test expires: 06/30/2010)
|
To
receive continuing education credit, you must read the
information in this article and take an on-line post
test and fill out an on-line program evaluation form.
The certificate will then be generated for you as a
.pdf file which you can print out locally on your computer.
CE Certification by ANNA requires a handling charge
that must be paid by credit card. Pricing information
is available by clicking on the "Post-Test Evaluation"
link below.
|
|
|
|
Please
download and print the PDF file below:
|
|
|
|
Colette B. Raymond, BScPharm, Pharm D,
MSc, ACPR
|
Colette B. Raymond, BScPharm, Pharm D,
MSc, ACPR, is a Clinical Pharmacist, Manitoba
Renal Program, Department of Pharmaceutical
Services, Health Sciences Centre Hospital,
Winnipeg, Manitoba, Canada.
|
|
Lori D. Wazny, BScPharm, Pharm D
|
Lori D. Wazny, BScPharm, Pharm D, is a
Clinical Pharmacist, Manitoba Renal Program,
Department of Pharmaceutical Services Health
Sciences Centre Hospital, Winnipeg, Manitoba,
Canada.
|
|
Patricia L. Honcharik, BScPharm, Pharm D,
ACPR
|
Patricia L. Honcharik, BScPharm, Pharm D,
ACPR, is a Senior Pharmacist, Psychiatry, Department
of Pharmaceutical Services, Health
Sciences Centre Hospital, Winnipeg, Manitoba,
Canada.
|
Depressive disorders occur in up to one-third of patients with chronic kidney disease
CKD). First-line pharmacologic treatments include selective serotonin reuptake
inhibitors and second generation agents, such as bupropion, mirtazapine, and venlafaxine.
Although very little research has been conducted on the use of antidepressants in
CKD, health care providers should be aware of renal dose adjustments for these agents,
drug interactions, and potential adverse effects. This article reviews the epidemiology
and significance of depression in patients with CKD and discusses drug therapy options
for treatment of depression in this patient population.
|
CE
RELATED INFORMATION |
|
This
offering for 1.5 contact
hours is being provided by
the
American
Nephrology Nurses’ Association
(ANNA), which
is accredited as a provider
and approver of continuing
education in nursing by
the American Nurses’
Credentialing Center-Commission
on Accreditation (ANCCCOA).
This educational activity
is approved by most states
and specialty organizations
that recognize the ANCC-COA
accreditation process. ANNA
is an approved provider of
continuing education in nursing
by the California Board of
Registered Nursing, BRN Provider
No. 00910; and the Kansas
State Board of Nursing, Provider
No. LT0148-0738. This offering
is accepted for RN and LPN
relicensure in Kansas.
|
|
Goal:
To provide information about the significance and treatment of depression in
patients with chronic kidney disease.
Objectives:
1. Review the epidemiology of depression in patients with CKD.
2. Relate the significance of depression in patients with CKD to the effect on nursing care.
3. Discuss the pharmacologic therapeutics used in the treatment of depression in patients with CKD.
|
AUTHOR DISCLOSURE
STATEMENT |
Colette B. Raymond
has no conflicts of interest to disclose.
Lori D. Wazny
has no conflicts of interest to disclose.
Patricia L. Honcharik
has no conflicts of interest to disclose.
|
ANNA and HDCN CE POLICY STATEMENTS |
The CE policy and disclosure statements of the American Nephrology
Nurses' Association are given in detail on the Symposium
Home Page. The CE policy statements of HDCN are listed on
this page. |
|
|
|
| |
